Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Sanara MedTech (SMTI) over the last 14 years, with Q3 2025 value amounting to -$774749.0.

  • Sanara MedTech's Cash from Financing Activities fell 10536.77% to -$774749.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 5894.01%. This contributed to the annual value of $17.4 million for FY2024, which is 8012.95% up from last year.
  • Sanara MedTech's Cash from Financing Activities amounted to -$774749.0 in Q3 2025, which was down 10536.77% from -$2.5 million recorded in Q2 2025.
  • Over the past 5 years, Sanara MedTech's Cash from Financing Activities peaked at $28.7 million during Q1 2021, and registered a low of -$2.5 million during Q2 2025.
  • Its 5-year average for Cash from Financing Activities is $4.0 million, with a median of -$144409.5 in 2022.
  • As far as peak fluctuations go, Sanara MedTech's Cash from Financing Activities crashed by 347547.67% in 2021, and later surged by 191972.67% in 2025.
  • Sanara MedTech's Cash from Financing Activities (Quarter) stood at -$442525.0 in 2021, then soared by 31.21% to -$304415.0 in 2022, then surged by 38.94% to -$185888.0 in 2023, then plummeted by 546.06% to -$1.2 million in 2024, then soared by 35.49% to -$774749.0 in 2025.
  • Its last three reported values are -$774749.0 in Q3 2025, -$2.5 million for Q2 2025, and $12.0 million during Q1 2025.